272 related articles for article (PubMed ID: 37808605)
1. An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review.
Dagli N; Kumar S; Ahmad R; Narwaria M; Haque M
Cureus; 2023 Oct; 15(10):e46510. PubMed ID: 37808605
[TBL] [Abstract][Full Text] [Related]
2. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
Tuchscherer RM; Thompson AM; Trujillo JM
Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006
[TBL] [Abstract][Full Text] [Related]
3. Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis.
Shou X; Wang Y; Duan C; Yuan G; Wei N; Yang Y; Hu Y
Curr Probl Cardiol; 2023 Aug; 48(8):101194. PubMed ID: 35395332
[TBL] [Abstract][Full Text] [Related]
4. The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs.
Joshi SR; Rajput R; Chowdhury S; Singh AK; Bantwal G; Das AK; Unnikrishnan AG; Saboo BD; Kesavadev J; Ghosal S; Mohan V
Diabetes Metab Syndr; 2022 Jun; 16(6):102508. PubMed ID: 35653929
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
6. Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review).
Tilinca MC; Tiuca RA; Niculas C; Varga A; Tilea I
Exp Ther Med; 2021 Oct; 22(4):1167. PubMed ID: 34504612
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.
Ruan Z; Yang L; Shi H; Yue X; Wang Y; Liang M; Hu H
Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):221-233. PubMed ID: 33317348
[No Abstract] [Full Text] [Related]
8. Trends of mitochondrial changes in AD: a bibliometric study.
Song R; Guo Y; Fu Y; Ren H; Wang H; Yan H; Ge Y
Front Aging Neurosci; 2023; 15():1136400. PubMed ID: 37261264
[TBL] [Abstract][Full Text] [Related]
9. Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.
Bandyopadhyay I; Dave S; Rai A; Nampoothiri M; Chamallamudi MR; Kumar N
Curr Drug Targets; 2022; 23(3):311-327. PubMed ID: 34468297
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG
Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100
[TBL] [Abstract][Full Text] [Related]
11. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
12. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
13. Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
Kim HS; Jung CH
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576096
[TBL] [Abstract][Full Text] [Related]
14. Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
Powell J; Piszczatoski C; Taylor JR
Clin Ther; 2020 Oct; 42(10):2100-2116. PubMed ID: 32873415
[TBL] [Abstract][Full Text] [Related]
15. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
Doggrell SA
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
17. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G; Krauthamer M; Bjalme-Evans M
J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
[No Abstract] [Full Text] [Related]
19. The published trend of studies on COVID-19 and diabetes: bibliometric analysis.
Li Y; Peng L; Gu W
Front Endocrinol (Lausanne); 2023; 14():1248676. PubMed ID: 37854183
[TBL] [Abstract][Full Text] [Related]
20. [Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].
Paquot N
Rev Med Liege; 2021 Dec; 76(12):896-903. PubMed ID: 34881835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
